Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Section 32 Information
Geographic Data
Address: -
City: Silicon Valley,
State: CA
Zip: 94024
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$1B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,606,848Website Global Rank
6,485Website Monthly Traffic
Twitter Followers
Description
Section 32, the new venture fund launched by Bill Maris, was named in homage to Section 31, an intelligence agency from the Star Trek universe. Maris, the GV (Google Ventures) founder/former-CEO, has raised $150 million for the project that will focus on various investments. The fund will be run directly by Maris and primarily based out of San Diego.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2022 | Parallel Finance | Venture Round | 0 |
| 5/2022 | Character Biosciences | Series A | 0 |
| 2/2019 | Teckro | Series C | 0 |
| 6/2021 | Primer | Series C | 0 |
| 5/2020 | Phaidra | Seed Round | 1.5M |
| 12/2021 | Dialpad | Series F | 0 |
| 3/2022 | SandboxAQ | Series D | - |
| 3/2021 | Meatable | Series A | 47M |
| 5/2021 | Phaidra | Seed Round | 0 |
| 7/2022 | Phaidra | Series A | 0 |
| 12/2021 | ONI | Series B | 75M |
| 7/2017 | Embark | Seed Round | 5.5M |
| 10/2018 | Nusano | Series A | - |
| 7/2020 | Sema4 | Series C | 121M |
| 2/2022 | Syllable | Series C | 0 |
| 1/2023 | Forward Networks | Series D | 0 |
| 4/2023 | Function Oncology | Series A | 28M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 7/2018 | Metromile | Series E | 90M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 3/2022 | Satellite Bio | Series A | 0 |
| 7/2022 | BigHat Biosciences | Series B | 0 |
| 10/2017 | Lime | Series B | 50M |
| 7/2018 | Cue | Series B | 0 |
| 9/2021 | Cohere | Series A | 40M |
| 10/2020 | Vineti | Series C | 33M |
| 2/2020 | Vineti | Series C | 35M |
| 4/2021 | C2i Genomics | Series B | 0 |
| 6/2021 | Syllable | Series B | 28M |
| 8/2019 | Sema4 | Series B | 120M |
| 7/2019 | Cradle Genomics | Series A | 0 |
| 1/2022 | Metaphysic | Venture Round | 7.5M |
| 6/2021 | ImmuneID | Series A | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 1/2021 | EQRx | Series B | 500M |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 6/2023 | AltPep | Series B | 0 |
| 12/2019 | XOKind | Pre Seed Round | 3.6M |
| 5/2022 | Legacy | Series B | 25M |
| 8/2020 | Freenome | Series C | 270M |
| 6/2021 | Faro | Series A | 15M |
| 12/2019 | XOKind | Seed Round | 3.3M |
| 2/2023 | Faro | Series A | 20M |
| 5/2017 | Kobalt | Series D | 75M |
| 10/2017 | Kobalt | Series D | 14M |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 8/2017 | Teckro | Series B | 10M |
| 10/2021 | Gretel | Series B | 0 |
| 7/2020 | Evidation Health | Series D | 45M |
| 12/2021 | Freenome | Series D | 300M |
| 10/2021 | ScienceIO | Seed Round | 0 |
| 12/2021 | Nodexus | Series A | 30M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 7/2018 | Octave Bioscience | Series A | 14M |
| 2/2018 | Celularity | Series A | 250M |
| 10/2017 | Dave | Series A | 13.3M |
| 6/2022 | Manifold Bio | Series A | 0 |
| 1/2019 | Ciitizen | Series A | 17M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 10/2021 | Culture Biosciences | Series B | 0 |
| 1/2020 | EQRx | Series A | 200M |
| 10/2022 | Neocis | Series D | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2018 | Fulcrum Therapeutics | Series B | 80M |
| 7/2017 | BloomAPI | Seed Round | 2.4M |
| 5/2019 | Thrive Earlier Detection | Series A | 110M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 10/2020 | Dialpad | Series E | 100M |
| 10/2020 | Neocis | Series D | 72M |
| 2/2022 | Cohere | Series B | 0 |
| 12/2021 | Verge Genomics | Series B | 98M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 7/2019 | Freenome | Series B | 160M |
| 4/2021 | Current Health | Series B | 43M |
| 5/2019 | MedCrypt | Series A | 6.3M |
| 8/2017 | Freenome | Series A | 7M |
| 3/2020 | Culture Biosciences | Series A | 0 |
| 9/2021 | TrialSpark | Series C | 156M |
| 11/2020 | WithMe Health | Series B | 25M |
| 11/2019 | Legacy | Seed Round | 3.5M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 12/2017 | Relay Therapeutics | Series B | 63M |
| 6/2019 | Legacy | Pre Seed Round | 1.5M |
| 12/2021 | Exai Bio | Series A | 67.5M |
| 4/2019 | Embark | Series A | 12M |
| 8/2017 | Coinbase | Series D | 108.1M |
| 12/2020 | Octave Bioscience | Series B | 32M |
| 8/2022 | Inworld AI | Series A | 0 |
| 9/2017 | Dialpad | Series C | 17M |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 6/2023 | Delve Bio | Series A | 0 |
| 2/2023 | Faro Health | Series A | 0 |
| 10/2021 | Wise Systems | Series C | 0 |
| 8/2022 | Spectral | Venture Round | 0 |
| 7/2018 | Dialpad | Series D | 50M |
| 11/2021 | Mekonos | Series A | 0 |
| 10/2022 | Stairwell | Series B | 0 |
| 2/2019 | Culture Biosciences | Venture Round | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 7/2022 | Swadesh | Pre Seed Round | 2.3M |
| 3/2022 | Nucleai | Series B | 0 |
| 11/2022 | MedCrypt | Series B | 0 |
| 11/2018 | Primer | Series B | 40M |
| 7/2018 | Alector | Series E | 133M |
| 4/2018 | Vineti | Series B | 33.5M |
| 11/2021 | MedArrive | Series A | 0 |
| 8/2017 | Auris Health | Series D | 0 |
| 2/2021 | Miroculus | Series B | 45M |
| 4/2023 | Function Oncology | Series A | 0 |
| 2/2023 | Faro Health | Series A | 0 |
| 1/2023 | Forward Networks | Series D | 0 |
| 11/2022 | MedCrypt | Series B | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2022 | Stairwell | Series B | 0 |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 8/2022 | Spectral | Venture Round | 0 |
| 8/2022 | Inworld AI | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
